$SGMT News

Sagimet Biosciences Presents Two Posters At EASL 2026; Denifanstat/Resmetirom Phase 1 Data Selected As Best Of EASL, With Additional Preclinical Mechanism Findings Showcased

Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $12

Sagimet Biosciences Q1 EPS $(0.33) Beats $(0.36) Estimate

Canaccord Genuity Maintains Buy on Sagimet Biosciences, Raises Price Target to $49

Guggenheim Maintains Buy on Sagimet Biosciences, Lowers Price Target to $25

Sagimet Biosciences Offering 29.17M Shares Of Series A Common Stock

Sagimet Biosciences Offering 29.17M Shares Of Series A Common Stock

Why Is Sagimet Biosciences Stock Trading Higher On Monday?

Sagimet Biosciences shares are trading higher. The company announced pricing of an underwritten offering of 29,166,700 shares of its Series A common stock at $6.00 per share.

Sagimet Biosciences Prices Underwritten Offering Of 29,166,700 Shares Of Series A Common Stock At $6/Shr For Gross Proceeds Of ~$175M

Sagimet Biosciences Plans To Initiate Phase 3 Clinical Trial Of Denifanstat In Moderate To Severe Acne Patients For US In H2 2026

Sagimet Biosciences Inc. (SGMT) Presents at Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium - Slideshow

Sagimet to Share Mid-Stage Liver Disease Drug Data at Medical Conference

HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target

Sagimet Biosciences Q4 EPS $(0.29) Beats $(0.48) Estimate

Sagimet Biosciences Inc. (SGMT) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

Guggenheim Initiates Coverage On Sagimet Biosciences with Buy Rating, Announces Price Target of $27

HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target

Sagimet Biosciences shares are trading higher after the company announced that Ascletis Pharma reported topline results in the open-label Phase 3 trial evaluating the long-term safety of ASC40 tablets in patients with moderate to severe acne.

Sagimet's Denifanstat: China Phase III Safety Data Isn't A Negative Signal